Drospirenone: a novel progestogen used as an oral contraceptive without an estrogen component.
Drospirenone
Female contraceptives
Fertility control
Mineralocorticoid receptor antagonists
Oral contraceptives
Progesterone receptor agonists
Progestogens
Journal
Drugs of today (Barcelona, Spain : 1998)
ISSN: 1699-3993
Titre abrégé: Drugs Today (Barc)
Pays: Spain
ID NLM: 101160518
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
entrez:
15
5
2020
pubmed:
15
5
2020
medline:
20
8
2020
Statut:
ppublish
Résumé
Drospirenone (DRSP) was synthesized as an analogue of spironolactone with the aim of producing a fourth-generation progestogen that differed from earlier progestogens in that it had antiandrogenic and little or no androgenic activity and lacked estrogenic effects while retaining some antimineralocorticoid activity. Since then, DRSP has been included in several oral contraceptive preparations together with an estrogen. However, increasing evidence has demonstrated that DRSP 4 mg on its own inhibits ovulation. It was thus a logical development to determine the efficacy of a tablet that only included DRSP 4 mg as an oral contraceptive. This proved successful and this product has now been approved by the Food and Drug Administration (FDA).
Identifiants
pubmed: 32406879
pii: 3134788
doi: 10.1358/dot.2020.56.5.3134788
doi:
Substances chimiques
Androstenes
0
Contraceptives, Oral
0
Estrogens
0
Progestins
0
drospirenone
N295J34A25
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
321-328Informations de copyright
Copyright 2020 Clarivate Analytics.